US › Healthcare

Senti Biosciences Inc (SNTI)

US · Healthcare · Biotechnology

$0.39+4.03%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$16,000

Net profit

$-4.2M

Profit YoY

+70.1%

EPS

$-0.14

EPS estimate

$-0.36

Net margin

-26,381.2%

EPS came in at -0.14 against a street estimate of -0.36 — a beat of 61.1%.

Key statistics

Market cap

$10.6M

Forward P/E

0.0

P/B

4.19

Book value

$0.08

EPS (TTM)

$-1.46

52-week high

$2.55

52-week low

$0.34

50-day MA

$0.85

200-day MA

$1.16

Beta

2.11

Analyst view

Analysts rate Senti Biosciences Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $13.50.

Shareholding

Insiders

47.91%

Institutions

18.54%

Largest institutional holders

Fund	Stake
NEA Management Company, LLC	12.12%
Nantahala Capital Management, LLC	2.85%
Geode Capital Management, LLC	0.66%
Menlo Ventures Management, L.P.	0.11%
BlackRock Inc	0.08%
XTX Topco Ltd	0.06%
Northern Trust Corp	0.05%
State Street Corp	0.03%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Senti Biosciences Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.